The lawsuit claims that Insulet failed to disclose critical defects in its manufacturing procedures, creating a foreseeable risk that its medical products would violate safety regulations or endanger patients. These omissions allegedly rendered the company’s public statements during the class period materially false and misleading, causing financial harm to shareholders who bought stock at artificially inflated prices.

The Gross Law Firm is currently seeking a lead plaintiff to represent the class. Shareholders interested in participating must register by the August 31, 2026, deadline. Participation in the action requires no immediate out-of-pocket costs, and the firm provides ongoing portfolio monitoring to keep registered investors updated on the case's progress.